FRESENIUS KABI, LLC holds $91.7M across 1,477 federal awards, concentrated at Department of Health and Human Services (HHS). Competition previously drew 5 offers. Set-aside status: NONE. Recompete timing centers on the Mar 13, 2030 PoP end — agencies typically plan 12–18 months ahead.
BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WATER
Current PoP ends Mar 13, 2030 (1325 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Sep 13, 2028.
Track recompete timing in SCOUT →FRESENIUS KABI, LLC — $91.7M obligated across 1,477 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. Free — no card required.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open FRESENIUS KABI, LLC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Register free to start exploring SCOUT →